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Abstract
Extracorporeal assistances are exponentially used for patients, with acute severe but reversible heart or lung failure, to
provide more prolonged support to bridge patients to heart and/or lung transplantation. However, experience of use
of extracorporeal assistance for pulmonary resection is limited outside lung transplantation. Airways management with
standard mechanical ventilation system may be challenging particularly in case of anatomical reasons (single lung),
presence of respiratory failure (ARDS), or complex tracheo-bronchial resection and reconstruction. Based on the
growing experience during lung transplantation, more and more surgeons are now using such devices to
achieve good oxygenation and hemodynamic support during such challenging cases. We review the different
extracorporeal device and attempt to clarify the current practice and indications of extracorporeal support
during pulmonary resection.
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Background
Locally advanced pulmonary cancers invading vital struc-
ture such as heart, great vessels, or carina cancer are gen-
erally considered as unresectable and incurable. Complete
resection in healthy tissue may be compromised due to
the proximity of the tumors to vital organs [1, 2]. Palli-
ation with chemotherapy and/or radiotherapy is the prin-
cipal means of treatment [1, 2]. Multimodality approach
with combination of both chemotherapy and radiotherapy
may downstage some patients with locally advanced pul-
monary cancer. In addition, progress in anesthesia
coupled with improved surgical techniques has helped re-
define the limits of resection [3]. In highly selected pa-
tients with specific anatomic conditions, complete R0
resection for locally advanced tumor has been reported
with prolonged survival and, on occasion, resulted in cure
[4–6]. Conventional techniques frequently do not allow
for complete resection of advanced pulmonary tumors in-
vading the heart or great vessels. Complex cardiac resec-
tions or reconstructions, replacement of the thoracic
aorta, or the common pulmonary artery can only be
approached with cardiac arrest and total circulatory sup-
port by standard cardio-pulmonary bypass (CPB) [7–10].
In contrast, for tracheo-bronchial surgery or single lung
situations, hemodynamic stability or cardiac arrest is not
mandatory [5]. However, standard mechanical ventilation
(jet-ventilation and/-or cross-field ventilation) may be in-
sufficient to achieve good oxygenation in complex
tracheo-bronchial resection and reconstruction [11].
Extracorporeal membrane oxygenation (ECMO) is a well-
established technique for the management of respiratory
or hemodynamic disturbance during lung transplantation
[12]. Intra-operative use of veno-venous (VV) or veno-
arterial (VA) ECMO allows good oxygenation in addition
to removal of CO2 and may provide a complete ventilator
support to complete tracheo-bronchial surgery or patient
with single lung or presenting lung failure [13–18].
Technological advances in pumps, cannulae, and oxygena-
tors and growing experience for thoracic surgeon during
lung transplantation have led to the use of ECMO during
conventional thoracic surgical procedure [13, 14]. Actu-
ally, ECMO experience for pulmonary resection is limited
to the description of clinical cases without real agreement
[18]. Pumpless interventional lung assist (Novalung) is an
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extracorporeal assistance which consists in a pumpless
membrane ventilator providing low oxygenation and good
carbon dioxide gas exchange and could be useful in se-
lected situations [19, 20]. The aim of this review is to re-
port current experience of the different extracorporeal
device available for the thoracic surgeon and clarify the
different indications.
Cardio-pulmonary bypass
In case of NSCLC invading the heart or great vessels,
conventional techniques allow a complete resection in
only 30 to 40 % of such cases [21]. Complex cardiac re-
sections or reconstructions, replacement of the thoracic
aorta, or the common pulmonary artery can only be
approached with a standard circulatory support by CPB.
Few authors have reported their experience of resection
of lung cancer with CPB [8, 22–28]. It has been esti-
mated that less than 0.1 % of all thoracic resections are
done by CPB [24].
Classical cardio-pulmonary bypass requires central
cannulation by standard sternotomy and pericardiotomy.
In different institutions, the introduction and the man-
agement of CPB is generally performed by cardiac sur-
geon. Normally, patients are placed on CPB with bi-
caval venous cannulation and arterial return in the as-
cending aorta. Full systemic heparinization is mandatory
with an ACT between 300 and 400 s and introduced be-
fore cannulation. Systemic hypothermia may be moder-
ate (32°) or profound (18°) depending on the extension
of resection and the vessels reconstruction. Cold-blood
potassium cardioplegia is required to protect myocar-
dium during the period of cardiac arrest, intra-cardiac
resection, and reconstruction.
The main advantage of CPB is to provide a complete
stability for gas exchange and hemodynamic support.
This stability gives the possibility of complete inspection
of infiltrated cardiac or vascular structure allowing for
safe resections margins which can be controlled intra-
operatively by frozen section. CPB may also promptly be
inserted in case of emergent situation due to great ves-
sels or heart lesions requiring reparation. However, CPB
may present some inconvenient due to the necessity of
full anticoagulation. Bleeding may be more frequent on
peri- or post-operative course requiring more transfu-
sion and re-operation for hemothorax [29]. Cardiac dis-
eases have been reported to increase the risk for
pulmonary complications following lung resections espe-
cially with prolonged use leading classically to pulmon-
ary oedema, reperfusion injury, acute lung injury, or
adult respiratory distress syndrome [22–25]. CPB may
also activate inflammatory mediators or potentially spill
tumor cells through the machine suction which could be
responsible for decreased survival rate [30]. There is also
a theoretical possibility of enhancement of metastasis
due to the immunosuppression caused by the pump and
blood transfusion [30–32].
There are been only five retrospectives studies of more
than five patients since 2000 reporting the use of CPB
for locally advanced pulmonary tumors or other intra-
thoracic malignancies presenting invasion of heart and/
or great vessels [22–25, 28] (Table 1). The indications
varied from curative intention to palliative treatment. All
series included restricted number of patients ranging
from 7 to 19 patients. The indication to surgical therapy
was made when no alternative treatment was available
and based on the individual situation of the patient.
Table summarizes the results of the current available
series. In four series, there was a mixture of tumor types,
mainly primary or metastatic sarcoma or pulmonary
carcinoma and one series reporting only on pulmonary
carcinoma. Concomitant lung resection consisted in pneu-
monectomy or lobectomy. Tumor invasion was restricted
to one structure or invading multiple regions of the heart
or great vessels such as aorta or pulmonary trunk. Heart
invasion consisted only in left or right atrial invasion.
There was no report on ventricular resection. In addition,
one patient had a resection of the right and left coronary
arteries and another patient required a coronary artery by-
pass grafting in the context of hemodynamically significant
two-vessel coronary artery disease discovered on the pre-
operative left heart catheterization. Emergent implementa-
tion of CPB was necessary in 33 % of patients (6/14) in the
series of Byrne et al. required by injury of vital structure:
superior vena cava (two patients), the inferior vena cava
(two patients), or the pulmonary artery (two patients) [25].
In five of six patients, a right thoracotomy had been used,
and emergent cannulation was achieved via the ascending
aorta and right atrium or via bi-caval cannulation. In the
remaining emergent patient, a left thoracotomy had been
used, and cannulation was achieved via the descending
thoracic aorta and the main pulmonary artery. In compari-
son, patients with planned surgery underwent central can-
nulation by sternotomy in five of the eight patients [25].
Sites of cannulation for CPB were mainly central with
bi-caval and ascending aorta cannulation. However,
some reported the use of peripheral access due to the
extension of infiltration. The duration of CPB varied
from 23 to 320 min. CPB achieved a complete cardiac
arrest in the majority of patients with the use of severe
hypothermia in one patient. In the series of De Perrot,
four of the seven patients have induction chemotherapy
or radio-chemotherapy [23]. Complete resection was
finally reported in almost 80 % of patients with 5-year
survival rate varying between 33 and 62 % depending on
the primary tumor type. Incomplete R2 resection was
achieved in some patient for palliative situation and
could however alleviate good palliation for bulky tumor
with median survival of 11 months [28].
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Table 1 Cardio-pulmonary bypass and pulmonary resection
Studies Number Primary tumor Lung resection Structure involved Morbidity Mortality (%) Survival
Vaporciyan. 2002 [22] 19 Sarcoma (n = 9)
Epithelial (n = 7)
Others (n = 1)
PN (n = 5)
Lobectomy (n = 3)
Great vessels (5 PA, 1 Ao, 5 IVC, 1 SVC)
Heart (5 LA, 6 RA)
Overall 58 %: Pneumonia (37 %)
Bleeding (21 %)
Tracheotomy (16 %)
11 Curative intent (median):
64 months
Palliative: 11 months
Park. 2004 [28] 10 Sarcoma (n = 7)
Others (n = 3)
PN (n = 2)
Lobectomy (n = 3)
Great vessels (5 SVC, 1 PA, 1 Aorta)
Heart (4 LA, 2 RA)
Overall 50 %
Re-operation 50 %
0 Complete resection
(median: 33.3 months)
De Perrot. 2005 [23] 7 NSCLC (n = 7) PN (n = 4)
Lobectomy (n = 2)
Carina (n = 1)
Great Vessels (2 SA, 1 Ao, 2 PA)
Heart (2 LA)
Carina 2
Overall (58 %) ARDS (1) 0 6/7 alive
Wiebe. 2006 [24] 13 Sarcoma (n = 8)
NSCLC (n = 3)
Others (n = 2)
PN (n = 9)
Lobectomy (n = 4)
Great Vessels (PA 6, PV 3, Ao 1, SVC 1)
Heart (LA 9, RA 3)
ALI (n = 4)
Right heart failure (n = 1)
MOF (n = 1)
15 Sarcoma 62 % at 5-year
NSCLC 33 % at 5-year
Byrne. 2004 [25] 14 NSCLC (n = 7)
Sarcoma (n = 5)
Mesothelioma (n = 1)
Thymic carcinoma (n = 1)
PN (n = 10)
Lobectomy (n = 3)
Wedge (n = 1)
Great vessels (PA 4, SVC 3, IVC 2
Heart (LA 3)
Low cardiac output syndrom (5/14)
Re-operation for bleeding (3/14)
Stroke (n = 1)
Pulmonary edema (n = 1)
0 21 % at 5-year
NSCLC non-small cell lung cancer, LA left atrium, RA right atrium, SVC superior vena cava, IVC inferior vena cava, Ao aorta, PA main pulmonary artery or pulmonary trunk, PN pneumonectomy, ALI acute lung injury
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Overall 30-day mortality ranged from 0 to 15 %. Over-
all morbidity was reported in more than 50 % of patients
consisting in pneumonia or acute lung injury. Park re-
ported that 50 % of patients requiring re-operation for
bleeding.
The use of CPB does not appear to increase the risk of
cancer dissemination with patient presenting long-term
survival. Moreover, several series have reported patients
with aortocoronary bypass surgery in combination with
pulmonary surgery during the same operative procedure
with good early and long-term results despite the use of
CPB [10, 33].
Based on these different series, no conclusion can be
drawn. In fact, there is actually no standard approach to
this complex situation. All existing studies showed dif-
ferent techniques of CPB, different extension of pulmon-
ary resection (lobectomy or pneumonectomy), different
sites of infiltration by the tumor (atrium, aorta, or pul-
monary trunk), types, and stages of tumors. Neverthe-
less, CPB is a feasible option of surgical therapy with or
without neo-adjuvant treatment for pulmonary or medi-
astinal malignancies invading cardiac structure and/or
great vessels. The choice of incision should be based first
on whether complete surgical resection, after which the
choice of cannulation sites should follow. The support of
CPB may increase the rate of a complete resection and
may improve long-term survival in highly selected pa-
tients provided that patient assumes the risk of high
morbidity and re-operation rate. Furthermore, the emer-
gent institution of CPB for the repair of injury to a vascu-
lar structure during pulmonary resection is lifesaving and
effective.
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO) repre-
sent a form of artificial circulatory and respiratory sup-
port used in the cases of respiratory or cardiac failure as
a bridge to restoration of the function or to further lung
transplantation. The published experience with this spe-
cific device in the mean of general thoracic surgery is
limited except for the ARDS, lung transplantation, and
neonatal-pediatric surgery for the management of differ-
ent congenital pathologies of the airways [12, 15, 16, 34].
ECMO use the concept of extracorporeal circulation
with the use of non-occlusive centrifugal pump and oxy-
genator which is responsible for enrichment of O2 and
elimination of CO2. A thermostat can be introduced to
the circuit to modulate the temperature. There is two
basic form of ECMO: veno-arterial and veno-venous.
These techniques assistance may be introduced periph-
erally or centrally depending on the specific indications
[34]. ECMO may provide optimal oxygenation with a
partial or total circulatory support. In comparison with
classical CPB, ECMO system may present some advantages:
the ECMO system needs theoretically low anticoagulation
(ACT: 160–200) with a low dose of heparin (500–1000 UI)
at the moment of the insertion of cannula provided that
the cannula are heparin-coated; the risk of thrombosis of
the ECMO system is very low during the short time of
thoracic operation. In case of important bleeding, anticoa-
gulation may be omitted. Others consider also that if
ECMO flow is more than 3l, heparin can be dispensed dur-
ing intra-operative use only [18]. There is no theoretical
risk of tumor cell dissemination due to closed system de-
void of cardiotomy suction during CPB. Moreover, ECMO
may present to surgeon a clean operative field without dis-
turbing line when cannula are introduced peripherally and
stability of cardio-respiratory function during heart ma-
nipulation [13]. ECMO may be maintained post-operatively
in case of pulmonary edema. ECMO may be also switched
from veno-arterial to veno-venous ECMO to obtain a pro-
tective lung ventilation avoiding pressure on bronchial or
tracheal sutures line in case of mechanical ventilation with
high volumes. Finally, in case of emergent situation, it is
possible to convert VA ECMO into conventional CPB by
adding a venous reservoir connected to the ECMO device.
Veno-arterial ECMO
Veno-arterial (VA) ECMO can support either the cardiac
and respiratory functions with good gas exchange and
cardiac hemodynamic support. This type of assistance is
recommended if the respiratory and cardiac support is
required. When cannula is inserted peripherally, the sites
of venous cannulation may be jugular interior vein or
femoral vein (17 to 19 French) to gain access to right
atrium. The oxygenated blood to the arterial circulation
is then re-injected into the femoral or axillary artery.
The insertion may be surgical or percutaneous provided
that femoro-femoral ECMO is the most used in emer-
gency situation due to the facility of vascular access in
the groin region. In neonatal patient, carotid artery has
been described as arterial cannulation. When central
cannulation is decided or required, the venous cannula
is inserted directly into the right atrium and the arterial
cannula positioned into the ascending aorta. The com-
plications of veno-arterial ECMO are mainly related to
the vascular access with potential arterial dissection at
the site of cannulation, or acute ischemia of the limb or
late arterial stenosis. A reperfusion cannula may be
inserted distally and connected to the arterial one in
order to bring oxygenated blood to the lower limb
through superficial femoral artery. Myocardial or brain
hypoxemia may be encountered when the heart is still
ejecting non-oxygenated blood while the lung is not ven-
tilated, with hypoxic blood from the left ventricle enter-
ing into the coronary and cerebral circulation. Harlequin
syndrome is characterized by competition of blood flow
between hypoxic blood ejected by the left ventricle and
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the blood oxygenated from the peripheral ECMO with
insufficient retrograde flow which could be responsible
of brain or myocardial damage [34]. The patient should
be correctly monitored with captor of blood saturation
on the upper part body, and situation promptly recog-
nized and required change of the type of ECMO.
Veno-venous ECMO
Veno-venous (VV) ECMO supports the lung only for
oxygenation and CO2 extraction. VV ECMO may be
used for elective cases in the absence of cardiac failure
or cardiac instability. The venous blood is aspired to the
reservoir, and after the passage by the oxygenator, the
blood is re-injected by a pump back to the venous sys-
tem. Unlike VA ECMO with potential arterial complica-
tions, VV ECMO needs only venous cannulation which
may be inserted in femoro-jugular or jugulo-femoral. Re-
cently, there has been the development of a double
lumen cannula inserted in the right jugular vein [35]. A
single site cannulation is only needed and be inserted
easily in the intensive care before the operation or in the
operating room. The double lumen cannula may be
maintained in post-operative course in case of post-
operative ARDS, and patient may be extubated and early
mobilized. The risk of re-circulation is theoretically de-
creased. This cannula should be positioned under both
control of transoesophageal echocardiography and fluor-
oscopy to avoid the risk of right ventricular perforation.
VV ECMO may fully support gas exchange and replace
ventilation leading to long period of apnea. Myocardial
and brain oxygenation is better maintained with oxygenated
blood getting directly through the systematic circulation.
Complications related to VV ECMO are thromboembolic
venous disease, superior vena cava syndrome, and re-
circulation [36].
Indications of ECMO
During thoracic surgery, airway management may be
sometimes problematic. The balance need to be obtained
between sufficient surgical exposure and adequate con-
trol of ventilation. This holds especially true for tracheo-
bronchial resection and reconstruction where selective
ventilation is required. Ventilation can be achieved by
two methods: the cross field periodic intubation of the
main bronchus alternating periods of apnea with ventila-
tion and jet ventilation through a small catheter passed
through the field into the contralateral main bronchus
[5]. These two techniques are generally sufficient for car-
inal resection and reconstruction. De Perrot reported
only 3 of 119 patients requiring emergency use of CPB
during carinal resection due to intra-operative edema of
the contralateral lung (n = 2) and major bleeding from
the right main pulmonary artery. However, these tech-
niques may present some limitations particularly in case
of severe tracheo-carinal stenosis where pre-operative
intubation is not feasible. CO2 removal during jet venti-
lation can be troublesome in patients with severe COPD
or obesity. Jet ventilation may also create barotrauma-
tism in the contralateral lung or may potentially cause
spilling of mucosal tumor cell spread. Furthermore, the
different tube in the operating field may impair the sur-
gical access and visibility leading to tension on anasto-
mosis during complex reconstruction. Good cooperation
with anesthesiologic team is required for tube placement
and replacement which can lead to period of long desat-
uration. Moreover, lack of hemodynamic stability may
appear if extended retraction maneuver of the heart are
needed.
In case of single lung procedure after previous pneu-
monectomy, ventilation can be managed by endotracheal
ventilation with high-flow oxygen through a small cath-
eter with tidal volume. However, this simple technique
may produce severe hypercapnic acidosis, and duration
of the technique is generally limited to 30 min. Finally,
in case of severe respirators failure, the surgeon needs to
operate with ventilated lung, but this technique does not
allow to perform complex surgical procedure.
The use of ECMO has been initially reported in the
pediatric population for the management of different
congenital tracheal pathologies requiring complex re-
construction with concomitant repair of artery sling or
patent ductus arteriosus [37–40]. These experiences in
infants allowed to determine potential implication for the
use of ECMO for adults: the use of ECMO could be bene-
ficial as a bridge to definite tracheal surgery; the use of
ECMO resulted in better visualization at the surgical site
without the need for endotracheal tubes and aggressive
ventilation technique. Finally, the ECMO allowed to
perform complex operative procedure under stable
cardio-respiratory conditions. In adult population, ECMO
is routinely used for the management of ARDS, severe
thoracic trauma, or during lung transplantation [34].
Thoracic surgeon is now more and more familiar with the
use of ECMO especially in the era of lung transplantation
[12]. ECMO may be inserted as a bridge during the wait-
ing period, during the operation in case of cardio-
pulmonary instability, or in the post-operative course in
case of primary graft dysfunction. The use of ECMO dur-
ing thoracic surgery other than lung transplantation has
been initially reported in 1996 by Horita who performed
two successful resections and reconstruction of the carina
under VV ECMO [41]. Since then, others reported
use of ECMO for complex tracheo-carinal resection
and reconstruction, during single lung procedure after
previous pneumonectomy or during ARDS: carinal re-
section [14, 42], mediastinal tumor resection with
compression of the trachea [43], single-lung segmen-
tectomy [44], tracheo-bronchial repair for traumatic
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Table 2 Extracorporeal device (ECMO veno-arterial and/or veno-venous) and pulmonary resection for pulmonary cancer
Series Number Primary tumor Pulmonary procedure Type of ECMO and duration Morbidity (ECMO) Outcome
Lang 2011 [14] 9 NSCLC (n = 7)
Carcinoid (n = 1)
Sarcoma (n = 1)
Complex tracheo-bronchial
resection (n = 6) associated
with pneumonectomy (n = 4)
or bilobectomy (n = 1)
Resection descending aorta
(n = 2)Resection inferior
vena cava (n = 1)
Central (n = 4)Peripheral
(n = 4)Combined (n = 1)
Mean time 110 min
(range 40 to 135)
- Lymphatic fistula to groin-
No bleeding- No vascular
thrombosis
Complete resection 8/9
(89 %)Mortality 1/9
(hepatic necrosis after
IVC resection)
Lang 2014 [13] 10 NSCLC (n = 7)
Carcinoid (n = 2)
Adenoid cystic (n = 1)
Carina (n = 6)
Sleeve lobectomy (n = 3)
Pneumonectomy (n = 1)
Central (n = 7)Peripheral
(n = 3)Mean time 113 min
(range 70–135)
- No bleeding-
No vascular thrombosis
Complete resection
8/10 (80 %) 5-year
survival 56 %
Rinieri 2014 [18] 36 NA Tracheo-carinal resection
(n = 21)Left main bronchus
resection (n = 2)Single-lung
surgeries (n = 5)Pulmonary
resection (n = 5)Thoracic
trauma (n = 2)
Veno-venous
(n = 20)Mean time 78 min
VA peripheral (n = 10)VA
central (n = 6)Mean time 65 min
Bleeding with re-operation
(n = 6)Bleeding cannulation site
(n = 1)Inguinal infection
(n = 1)No thrombosis or
ischemia limb
30-day mortality
17 % (n = 6)
Redwan 2015 [49] 9 NSCLC (n = 6)Pulmonary
metastases (n = 2)COPD
(n = 1)
Segmentectomy (n = 3)
lobectomy with bronchial
and vascular anastomoses
(n = 1)VATS lobectomy (n = 2)
Left-sided carinal pneumonectomy
(n = 1)Metastasectomy (n = 2)
Veno-venous (n = 9)Mean
time 19 min (range: 71–184)
Pneumonia (n = 5)
Tracheostomy (n = 1)
Acute cardiac failure (n = 1)
30-day mortality
11 % (n = 1)
NA not available
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Table 3 Summary of different extracorporeal devices
Inconvenient Longer operations
➢ Cardiac disease have been reported to increase the risk for pulmonary complications following lung resections
especially with prolonged use (pulmonary oedema)
➢ Full anticoagulation (ACT >300 s)
➢ Bleeding (transfusion, re-operation)
➢ Activation of inflammatory mediators
➢ Potential danger of tumor cell spilling through the machine suction
Cardio-pulmonary
bypass
Indication
➢ Total pulmonary support (CO2 extraction and O2) hemodynamic stability and possibility of cardiac arrest
Advantage
➢ Complete inspection of infiltrated cardiac or vascular structures allowing for safe resections margins
➢ Intra-operative microscopic control of complete resection
➢ Emergent institution in case of great vessels lesion
Inconvenient Longer operations
➢ Cardiac disease have been reported to increase the risk for pulmonary complications following lung
resections especially with prolonged use (pulmonary oedema)
➢ Full anticoagulation (ACT >300 s)
➢ Bleeding (transfusion, re-operation)
➢ Activation of inflammatory mediators
➢ Potential danger of tumor cell spilling through the machine suction
Veno-arterial ECMO Indication
➢ Total pulmonary support (CO2 extraction and O2) and hemodynamic stability
Advantage
➢ No risk of tumor cell dissemination (closed system devoid of cardiotomy suction)
➢ Low anticoagulation (ACT:160-200 s). Cannulae are heparin-coated
➢ Clean operative field without disturbing line
➢ Stability of cardiorespiratory function during heart manipulation
➢ Switch VA to VV ECMO: protective lung ventilation (no pressure on sutures in case of mechanical
ventilation with high volumes). VA ECMO can be quickly converted into conventional CPB in
case of cardiovascular wound
Inconvenient
➢ Arterial dissection/thrombosis
➢ Acute ischaemia of limb
➢ Myocardial or brain hypoxaemia
Veno-venous
ECMO
Indication
➢ Total pulmonary support (CO2 extraction and O2)
Advantage
➢ Useful for elective cases if no cardiac failure or cardiac morbidity
➢ No arterial cannulation with no risks of arterial injury
➢ Better myocardial oxygenation
➢ Possibility to maintain post-operatively in case of pulmonary oedema
Inconvenient
➢ Thromboembolic venous disease
➢ Recirculation
➢ Superior cava syndrome
Interventional lung
assist (Novalung)
Indication
➢ Partial pulmonary support (CO2 extraction, low oxygenation)
Advantage
➢ Pumpless membrane ventilator
➢ Low anticoagulation
➢ Apnea possible with passive endotracheal oxygenation
➢ Peripheral access by percutaneous cannulation
Inconvenient
➢ Vascular access complications (dissection, thrombosis)
➢ Only part of the cardiac output (1–2 L/min) for extracorporeal gas exchange. (Low capacity of oxygenation)
➢ Adequate mean arterial blood pressure is mandatory. It may not be used as:o Low cardiac outputo Impaired
left ventricular functiono High dose catecholamine administration
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injury [45, 46], emphysemateous bulla resection in
single lung, or limited resection of the lung (wedge
or segmentectomy) for aspergillosis or lung abscess
during ARDS [47, 48].
Lang et al. reported their experience in two recent
series with the use of veno-arterial ECMO for complex
tracheo-carinal resection for central tumor [13, 14]
(Table 2). Carinal resection and reconstruction was asso-
ciated in some patients with pulmonary resection (pneu-
monectomy or lobectomy). Cannula was implanted both
in peripheral or central position depending on the
planned surgical approach. The mean time of ECMO
was 110 and 113 min. Interestingly, they do not report
complication related to the ECMO device or cannula ac-
cess with no bleeding or arterial complications. They
could achieve a complete R0 resection in more than
80 % with an interesting 5-year survival rate of 56 %.
They described total cardio-pulmonary stability and
clean operative field allowing for safe resection and re-
construction. They used low anticoagulation with hep-
arin with ACT below 200 s. Recently, Rinieri et al.
reported a national review of the use of ECMO as re-
spiratory support in thoracic surgery excluding lung
transplantation and lung resection for tumors invading
the great vessels and/or the left atrium with a question-
naire in 34 thoracic centers in France taking into ac-
count years 2009–2012 [18]. There were 17 centers that
applied ECMO in 36 patients. The type of ECMO and
type of resection are resumed in Table 3. Total respiratory
support with VV (n = 12) or VA (n = 16) with interruption
of ventilation was required in 28 patients for tracheo-
bronchial (n = 23) and single-lung (n = 5) procedures.
Time off ventilation median duration during ECMO was
78 and 65 min for VV and VA ECMO, respectively.
ECMO morbidity consisted in bleeding requiring re-
operation in six patients (17 %) and two cannulation-
related complications (6 %). Overall 30-day mortality was
17 % (n = 6).
Based on their report, Rinieri et al. proposed a simple
algorithm for the use of ECMO based on the degree of
emergency, the necessity of hemodynamic support, and
the surgical access (Fig. 1) [18]. In case of emergent situ-
ation (major bleeding or cardiac instability), VA ECMO
should be privileged either by femoral cannulation if the
patient lies on supine position or in central position if
surgical access allows central cannulation. Hemodynamic
instability due to cardiac failure, pulmonary hypertension,
or major cardiac retraction necessitates VA ECMO for
circulatory support. In case of tracheo-carinal resection,
VV ECMO by dual-lumen cannula inserted in the right
jugular vein seems guaranteed enough respiratory support
in the absence of hemodynamic disturbance. Redwan et
al. reported their experience with veno-venous ECMO for
major resection. VV ECMO allowed apnea for 40 min, time
necessary for resection and reconstruction of complex pro-
cedure such as left sided carinal pneumonectomy [49].
In conclusion, the use of ECMO remains exceptional
and reported in small collectives of patients. However,
VV and VA ECMO may be useful as total respiratory
support in complex tracheo-bronchial surgery or single-
lung surgery where conventional ventilation technique is
not feasible. The choice between VA and VV ECMO de-
pends on the need of circulatory support, surgical ac-
cess, and current practice.
Pumpless interventional lung assist (Novalung)
Pumpless interventional lung assist (iLA) consists of a
pumpless membrane oxygenator that is driven by the
Fig. 1 algorithm for insertion of ECMO in case of elective or emergent thoracic surgery (adapted from Rinieri et al. [18]
Rosskopfova et al. World Journal of Surgical Oncology  (2016) 14:25 Page 8 of 10
difference in arterial and venous blood pressure [19].
Only part of the cardiac output (1–2 L/min) is accessible
for extracorporeal gas exchange reason why this system al-
lows only good CO2 removal, but low oxygenation. As the
system is pumpless with an arterio-venous configuration,
an adequate mean arterial blood pressure is mandatory.
The preferred access sites are the femoral vessels (venous
19F /arterial 17F) by percutaneous cannulation using Sel-
dinger’s technique. All the components of the system are
heparin coated, and generally, it is recommended a single
bolus injection of 500 to 1000 units of heparin before
introduction of the cannula.
Wiebe et al. reported ten patients who underwent
thoracic surgical procedure under the Novalung device
[20]. Six of them required Novalung on emergent situ-
ation. Five patients required lung surgery for single-lung
situation (wedge, decortication, bronchial repair, and
esophageal resection). The average flow of Novalung was
1.58 L/min allowing adequate CO2 extraction and cor-
rection of the pH in all patients. In addition, oxygen-
ation was managed with administration of oxygen 100 %
in the trachea via endotracheal small bore catheter at
low pressure (3–10 mmHg) allowing apneic oxygenation
in four patients up to 60 min. They reported retroperi-
toneal hematoma after percutaneous removal of arterial
cannula related to device.
Although Novalung is capable of controlling any hy-
percapnic complications, its capacity for oxygenation is
limited in comparison with ECMO. Furthermore, this
pumpless extracorporeal lung assist required good car-
diac function and should cautiously used in case of low
cardiac output, impaired left ventricular function or ad-
ministration of high dose of catecholamine. Moreover,
complications have been reported in 10 to 24 % related
to access device [50]. In conclusion, the Novalung device
could be an alternative in case of pure hypercapnic situa-
tions without impairment of oxygenation or hemodynamic
stability. Hypoxemic situation after implementation can be
managed with adjunction of low-pressure oxygen allowing
for period of apnea reaching up 1 h in selected cases.
Conclusions
Cardio-pulmonary bypass, extracorporeal membrane oxy-
genation, and pumpless extracorporeal lung assist have
their place in the general thoracic surgery considering that
a growing number of patients will benefit complex resec-
tion due to the advance in oncological treatment and im-
provement in surgical and anesthesic techniques. The
choice of the right device depends on the type of surgery
and the type of cardio-respiratory status. Carefully se-
lected patients with tumor involvement of the heart or
great vessels should be resected on CPB with acceptable
mortality and morbidity. It allows achievement of good
palliation and long-term survival in a few. VV and VA
ECMO can serve as total respiratory support in complex
tracheo-bronchial surgery or single lung surgery where
conventional ventilation techniques are not feasible. VA
ECMO is a choice in patients where cardiac support is
needed compared to VV ECMO that sustains respiratory
functions only. Pumpless extracorporeal lung assist device
with passive endotracheal oxygenation could be an alter-
native for patient without hypoxemic or hemodynamic in-
stability. A combined and well-coordinated effort among
the general thoracic surgeon, the cardiac surgeon, the per-
fusionist, and the anesthesiologist is required for a suc-
cessful outcome. All those methods are feasible but are
reserved to centers with extensive experience and practice
handling of those systems.
Abbreviation
CPB: cardio-pulmonary bypass; ECMO: extracorporeal membrane
oxygenation; VA: veno-arterial; VV: veno-venous.
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